来法莫林
Tier C — Watch / tradeLefamulin
Targets：50S ribosomal subunit
Brand：信乐妥、Xenleta
Indications (approved)：感染、社区获得性感染、细菌性肺炎、肺炎、社区获得性肺炎
Regional status
Synthetic routes & intermediates2 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| LEFA-001 | - | (3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]annulen-5-yl 2-iodoacetate |
| LEFA-002 | - | (3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]annulen-5-yl 2-(carbamimidoylthio)acetate |
| LEFA-003 | 70004-29-4 | (3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]annulen-5-yl 2-mercaptoacetate |
| LEFA-004 | 1350636-88-2 | tert-butyl ((1R,3R,6S)-7-oxabicyclo[4.1.0]heptan-3-yl)carbamate |
| LEFA-005 | 1350636-76-8 | (3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]annulen-5-yl 2-(((1R,2R,4R)-4-((tert-butoxycarbonyl)amino)-2-hydroxycyclohexyl)thio)acetate |
| Code | CAS No. | Intermediate |
|---|---|---|
| LEFA-005 | 1350636-76-8 | (3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]annulen-5-yl 2-(((1R,2R,4R)-4-((tert-butoxycarbonyl)amino)-2-hydroxycyclohexyl)thio)acetate |
| LEFA-006 | 4771-80-6 | cyclohex-3-ene-1-carboxylic acid |
| LEFA-007 | 2627-86-3 | (S)-1-phenylethan-1-amine |
| LEFA-008 | 67976-81-2 | (S)-1-phenylethan-1-aminium (R)-cyclohex-3-ene-1-carboxylate |
| LEFA-009 | 5709-98-8 | (R)-cyclohex-3-ene-1-carboxylic acid |
| LEFA-010 | 1350636-87-1 | tert-butyl (R)-cyclohex-3-en-1-ylcarbamate |
| LEFA-011 | 1350636-88-2 | tert-butyl ((1R,3R,6S)-7-oxabicyclo[4.1.0]heptan-3-yl)carbamate |
| LEFA-012 | 1350636-89-3 | S-((1R,2R,4R)-4-((tert-butoxycarbonyl)amino)-2-hydroxycyclohexyl) benzothioate |
| LEFA-013 | 1350636-75-7 | tert-butyl ((1R,3R,4R)-3-hydroxy-4-mercaptocyclohexyl)carbamate |
| LEFA-014 | 31716-01-5 | (3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]annulen-5-yl 2-(tosyloxy)acetate |
Frequently asked questions
What are the approved indications of Lefamulin?
Approved indications include: 感染, 社区获得性感染, 细菌性肺炎, 肺炎, 社区获得性肺炎.
When does the Lefamulin patent expire?
No public expiry year is available for Lefamulin yet; this page updates once verified.
How many synthesis routes are recorded for Lefamulin?
2 synthesis routes are recorded; the shortest is 5 steps with 3.63 g total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Lefamulin intermediates?
All intermediates in Lefamulin routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Lefamulin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24